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Backgrounds: Survival analysis is commonly used to determine the treatment effect among acute lymphoblastic
leukemia (ALL) patients who undergo allogeneic stem cell transplantation (allo-SCT) or other treatments. The aim
of this study was to evaluate the use and reporting of survival analyses in these articles.
Methods: We performed a systematic review by searching the MEDLINE, EMBASE and Cochrane library databases
from inception to April 2015. Clinical trials of patients with ALL comparing allo-SCT compared to another treatment
were included. We included only studies that used survival analysis as a part of the statistical methods.
Results: There were 14 studies included in the review. Sample size estimation was described in 4 (29 %) studies.
Only 4 (29 %) studies reported the list of covariates assessed in the Cox regression and 6 (43 %) studies provided a
description of censorship. All studies reported survival curves using the Kaplan-Meier method. The comparisons
between groups were investigated using the log-rank test and Wilcoxon test. Crossing survival curves were
observed in 11(79 %) studies. The Cox regression model was incorporated in 10 (71 %) studies. None of the studies
assessed the Cox proportional hazards assumption or goodness-of-fit.
Conclusions: The use and reporting of survival analysis in adult ALL patients undergoing allo-SCT have significant
limitations. Notably, the finding of crossing survival curves was common and none of the studies assessed for the
proportional hazards assumption. We encourage authors, reviewers and editors to improve the quality of the use
and reporting of survival analysis in the hematology literature.
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Survival analysis measures the time from a defined start-
ing point to the occurrence of an interested event where
the risk changes over time. The goals of survival analysis
serve three purposes: (1) to estimate survival and hazard
functions from survival data, (2) to compare survival
and hazard functions between groups and (3) to assess
the relationship between predictor variables and survival
time. The essential components for survival analysis
include the time to event and the binary event outcome
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(http://creativecommons.org/publicdomain/zeThe probability of survival can be represented generating
a Kaplan-Meier (KM) curve from survival data. Indeed, the
KM plot is based on the estimate of the conditional
probability of the time to failure [1] calculated at each time
point recording an event. The difference in survival
between two or more groups (or the treatment effect if
treatment is what defines the two groups) can be com-
monly compared using the log-rank test [2].
The Cox proportional hazard (PH) model is a widely
used regression method for survival data. The Cox PH
model estimates the effect of predictor variables using
the hazard function which does not require specifying a
baseline hazard rate [3]. The measure of the effect,
unadjusted or adjusted for covariates, is demonstrated as
a hazard ratio (HR) which is expressed as an exponent
of a regression coefficient in the model. An importantle is distributed under the terms of the Creative Commons Attribution 4.0
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tion requires the hazard ratio to be constant over time
[4]. Therefore, the Cox PH model is considered to be a
semi-parametric model. Other regression models that
can be used for survival analysis include an extended
Cox PH model or parametric survival model (Weibull,
exponential, log-logistic, lognormal, etc.) [5].
A recent systematic review demonstrated that survival
analysis was incorporated in only 29 % of internal
medicine articles [6]. However, there has been an in-
creasing trend to using survival analysis in all categories
of medical journals [6].
Allogeneic stem cell transplantation (allo-SCT) is
the most potent post-remission therapy in adult
acute lymphoblastic leukemia (ALL). The benefit of
allo-SCT in adult ALL remains controversial [7].
Survival analysis is generally used to determine the
treatment effect among ALL patients who undergo
allo-SCT or other treatments, both in terms of
prolongation and increased likelihood of survival.
Allo-SCT is associated with high treatment-related
mortality. Patients who tolerate the treatment are
more likely to have a prolong event free survival and
overall survival. On the other hand, non allo-SCT is
less intensive treatment but may be associated with
lower long-term event free survival. ALL literature
were chosen because we expected that the use and
report of survival analysis in such articles are compli-
cated. To investigate whether the heterogeneity in
study results is at least in part explained by a more
or less appropriate use of time to event analysis, we
conducted a systematic review of clinical trials which
investigated the efficacy and safety of allo-SCT in
adult patients with acute ALL. The aim of this study
was to evaluate the use and reporting of survival
analyses in these articles.Methods
Data sources
We performed a systematic review by searching in
the MEDLINE, EMBASE and The Cochrane library
(The Cochrane Register of Controlled Trials and
Cochrane Database of Systematic Reviews) databases.
The reference lists were searched from the retrieved
articles. The search terms were: Bone Marrow Trans-
plantation OR Hematopoietic Stem Cell Transplant-
ation OR Peripheral Blood Stem Cell Transplantation
AND nonmyeloblat* OR non-myeloblat* OR Precur-
sor Cell Lymphoblastic Leukemia-Lymphoma OR
lymphoblast* OR lymphoid. AND (random* OR RCT
OR control* OR trial). The database search was
performed from inception to April 2015 with no
language restrictions.Selection criteria
The studies were included if they met the following
criteria; were a clinical trial, controlled clinical trial or
randomized control trial with allo-SCT compared to au-
tologous SCT or non-transplantation therapy in patients
with ALL in first complete remission. We only included
studies that used survival analysis as one of the statistical
methods.
Study selection and data extraction
Two investigators (CC and CH) independently identified
articles using predefined inclusion criteria. Disagree-
ments were resolved by consensus. Two investigators
(CC and CH) independently extracted the data using a
standardized data extraction from. Disagreements were
again resolved by consensus.
We collected the following data: study design, out-
come of interest (death, relapse), number of patients and
number of events, survival curves estimate, regression
method to estimate the hazard rate (Cox PH model or
parametric survival model), methods for comparing the
survival curves, the shape of the survival curves, variable
selection, model building strategy, censoring description,
length of follow-up, sample size calculation, test of
interaction between variables, test for time dependent
covariates, test for proportionality assumption and test
for goodness-of-fit.
Analytic criteria
To evaluate the quality of reporting survival analyses, we
used the following list of criteria for the proper use and
description of the survival analyses.
1. Sample size: We evaluated the methods that the
investigators described for sample size calculation.
In addition, in the studies that used multiple
regression analysis we evaluated the number of the
events and number of covariates in order to estimate
the adequacy of power. According to Peduzzi et al.,
approximately ten events per covariate is
appropriate in PH regression analysis [8].
2. Censoring description: We evaluated the description
of censoring and whether the investigators reported
this adequately, inadequately or there was no mention.
3. Survival curves: We evaluated the statistical methods
used for generating survival curves. For the
comparison of survival between the groups, we
documented the reported methods (log-rank test
or Wilcoxon test). We also noted the shape of the
survival curves (evenly separated or crossing
survival curves).
4. Statistical significance: The statistical test used to
evaluate the difference between two survival curves
is determined using a log-rank test or weighted
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of the test is that there is no difference between the
two survival curves. We documented the statistical
test reported in the articles.
5. Regression model: The statistical methods used for
survival regression analysis were evaluated. We
were interested in the regression model that the
investigators used for calculating the hazard ratio
(e.g. Cox PH model, extended Cox PH model or
parametric survival model). We were also interested
in the other regression models (time-dependent
variable, competing risk analysis or repeated event
analysis). In addition, the test for interaction of the
variable was checked. For the studies that used
multivariate regression, we assessed the description
of variable selection and the strategy used for
model building.
6. Check for the PH assumption: We assessed the test
for PH assumption described in the articles. The
assessment included methods used for checking
PH assumption (graphical approach or the
goodness-of-fit testing approach).
7. Model checking: We evaluated whether the
investigators assessed for goodness-of-fit measures.
The residual-based diagnostics were also assessed
(martingale residuals, Cox-Snell residuals,
Schoenfeld residuals or deviance residuals).
Results
Study characteristics
A total of 881 citations were identified by the systematic
search strategy. Of these, 325 studies were duplicates.
After screening of the titles and abstracts using prede-
fined inclusion criteria, 541 studies were excluded. The
reasons for exclusion are summarised in Fig. 1. Of these,Fig. 1 Flow diagramwe identified 15 potential studies for full-text review.
Two studies were identified following manual review
of the references. We excluded three studies due to
no clinical trials comparing allo-SCT with other treat-
ments. Thus, 14 studies [9–22] were included in our
systematic review.
The study characteristics are summarised in Table 1. All
of the studies were clinical trials. Patients were random-
ized to receive either allo-SCT or other treatments
(autologous SCT or consolidation chemotherapy). Patients
were allocated to undergo allo-SCT if the patient had a
human leukocyte antigen (HLA) matched sibling donor,
otherwise, the patient received autologous SCT or consoli-
dation chemotherapy according to the study protocols.
The median follow-up ranged from 59 to 114 months.
The time-to-event outcomes in the included studies were
overall survival and disease-free survival.
Analytic criteria
1. Sample size
Sample size estimation was described in 4 of 14
studies (Table 2). The proportion of events per total
patients ranged from 36 to 78 %. With respect to
the sample size and number of covariates assessed in
the regression analysis, only four studies reported
the list of covariate assessed in the Cox regression
model. Of these, two studies obtained more than
ten events-per-covariate (event-per-covariate 20.4
and 23.2, respectively) [11, 13]. However, the
other two studies had an event-per-covariate
8.3 [20] and 3.8 [22].
2. Censoring description
There were six studies that provided the censoring
description.
Table 1 Study characteristics




Attal [9] 41 64 30 DFS Randomized trial
Bernasconi [10] 11 29 48 DFS Clinical trial
Cornelissen [11] 96 161 65 OS, DFS Clinical trial
De Witte [12] 30 33 60 OS, DFS Clinical trial
Fielding [13] 81 77 98 OS, DFS Clinical trial
Goldstone [14] 443 588 59 OS, DFS Clinical trial
Hunault [15] 41 106 61 OS, DFS Randomized¶ trial
Ifrah [16] 18 32 60 DFS Clinical trial
Labar [17] 68 116 114 OS, DFS Clinical trial
Ribera [18] 84 98 70 OS, DFS Clinical trial
Sebban [19] 116 141 62 OS, DFS Clinical trial
Thomas [21] 100 159 62 OS, DFS Clinical trial
Takeuchi [20] 34 108 63 OS, DFS Clinical trial
Ueda [22] 17 40 62 OS, DFS Clinical trial
Genetically randomization
Abbreviation: Allo-SCT allogeneic-stem cell transplantation, DFS disease free survival, OS overall survival
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All studies reported survival curves using the KM
method. The comparisons between the groups were
investigated using a log-rank test in all studies (two
studies used both log-rank test and Wilcoxon test).
With regards to the shape of the survival curves, 11
studies reported crossing survival curves [9–15,
17–20] whereas one study reported unevenly
separate survival curves [21] and one study reported
evenly separated survival curves [22]. The overlapping
survival curves were observed in five studies [9, 12,
14, 17, 20]. We were not able to compare survival
curves in one study where the graphs were plotted
in the separately [16].
4. Statistical significance
All of the studies reported the statistical test used to
measure the difference between survival curves. Of
these, five studies reported statistical significance for
the treatment effect between groups. However,
eight studies reported non-statistical significance
(one study did not report).
5. Regression model
The regression model was incorporated in 10 of 14
studies. All ten studies used the Cox PH model
[9, 11, 14–18, 20–22]. There was no parametric
survival analysis used in the included studies.
One study mentioned the test for interaction
and competing risk analysis [11]. None of the
studies described variable selection. Only one
study mentioned the strategy used for model
building [18].6. Check for the PH assumption
In studies that used Cox PH model, PH assumption
checking was not mentioned in any of the studies
that used Cox PH model.
7. Model checking
The summary measures of the regression diagnostic
and goodness-of-fit were not mentioned in any of
the studies.
Discussion
Our study demonstrates that survival analyses have been
used extensively in the landmark trials evaluating all-
SCT in adult patients with acute ALL. However, the
majority of the trials poorly reported their statistical
methods and results. Sample size estimation and censor-
ing description were not routinely described. Almost all
the presented survival curves crossed. Moreover, the
Cox assumption was not assessed even if the investi-
gators used the Cox PH model. In addition,
goodness-of-fit or regression residual analysis were
lacking in all of the trials.
Regarding the sample size estimation, according to
Consolidated Standards of Reporting Trials (CONSORT),
it is important that the authors indicate how sample size
was determined [23]. The intent of the sample size estima-
tion is to ensure that a particular study has sufficient
statistical power to detect a difference in the treatment
effect between groups. Our review demonstrates that only
4 of 14 (29 %) trials described a sample size estimation.
With respect to the regression analysis, only four studies
provided a full list of covariates. Of these, only two studies
Table 2 Reporting survival analyses in the included studies
Study Sample size
estimation
Event/total Censoring Survival curve Shape of KM-curve Significance Regression model Variable selection Goodness of fit or
PH assumption test
Attal [9] Yes 86/135 (relapse) NR KM method, log-rank test Crossing, overlapping S Cox-PH model Informal NR
Bernasconi [10] NR NR NR KM method, log-rank test Crossing NS N/A N/A NR
Cornelissen [11] NR 102/257 (death),
113/257 (relapse)




De Witte [12] NR 32/66 (death) NR KM method, log-rank test,
Wilcoxon test
Crossing, overlapping S N/A N/A NR
Fielding [13] NR 116/165 (death) NR KM method, log-rank test Crossing NS N/A N/A NR
Goldstone [14] NR 531/1031 (death) Yes KM method, log-rank test Crossing, overlapping NS Cox-PH model N/A NR
Hunault [15] Yes 67/147 (death) NR KM method, log-rank test Crossing S Cox-PH model Informal NR
Ifrah [16] Yes 37/50 (relapse) NR KM method, log-rank test Curves were plotted
in two different graphs
N/A Cox-PH model Informal NR
Labar [17] NR 245/340 (death),
131/340 (relapse)
Yes KM method, log-rank test Crossing, overlapping NS Cox-PH model Informal NR
Ribera [18] Yes 144/182 (death),
88/182 (relapse)
Yes KM method, log-rank test Crossing NS Cox-PH model Informal NR
Sebban [19] NR 146/255 (death) NR KM method, log-rank test Crossing NS N/A N/A NR
Thomas [21] NR 177/259 (relapse) NR KM method, log-rank test Unevenly separate S Cox-PH model Informal NR
Takeuchi [20] NR 83/142 (death) Yes KM method, log-rank test Crossing, overlapping NS Cox-PH model Informal NR
Ueda [22] NR 38/57 (death) Yes KM method, log-rank test,
Wilcoxon test
Evenly separate S Cox-PH model Informal NR
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ratio more than 10).
In survival analysis, patients who do not experience
the relevant outcome over the study period, patients
who are lost to follow-up during the study period and
patients who withdraw from the study are censored.
There are three assumptions regarding censorship in
survival analysis: independent, random and non-
informative [4]. Thus, the description of censorship is an
important aspect to report in publication. However, only
6 of 14 (43 %) trials described their censoring. More
importantly, if relapse is the outcome of interest in these
studies, patients who die from any cause will be
censored. In this circumstance, censoring may be
considered informative because patients may die from
disease progression or treatment-related causes.
Consequently, the results may change based on differ-
ent censoring descriptions. Providing a definition of
censorship is a critical component to reporting these
trials in the literature.
All of the studies utilized survival curves. Not
surprisingly, crossing survival curves were found in 10 of
14 studies. Allo-SCT is considered the most potent post
remission therapy in adult ALL [24]. In long-term
follow-up studies, the patients who underwent allo-
SCT had a lower relapse rate due to a graft-versus-
leukemia effect [11]. However, these patients had a
higher early mortality rate from the toxicity of
myeloablative chemotherapy when compared with
patients who received autologous SCT or consolida-
tion chemotherapy [11, 13]. Therefore, survival curves
comparing these two treatments may be expected to
cross at some point. Early death from treatment-
related complications (commonly found in allo-SCT)
and late death from relapsed disease (commonly
found in autologous SCT) should be taken into the
account in the treatment of ALL. Crossing survival
curves make the interpretation of the treatment ef-
fects from the interventions much more complicated.
The log-rank test is the most common method used to
compare the difference between survival curves based
on the chi-square test [25]. It is important to note that
the log-rank test may be invalid if the survival curves
cross because of an increase of the probability of type
II error. Moreover, the log-rank test may lose power
in the circumstance of crossing survival curves [26].
Our study reveals that, among ten analyses with
crossed survival curves, eight were non-statistically
significant and two were statistically significant. We
found that five studies had overlapping survival
curves that might be explainable for insignificant find-
ings of the interventions. It was difficult to make a
conclusion on the rest of the studies based on the
log-rank test of crossing over survival curves.Strategies have been proposed to overcome the limita-
tion of the log-rank test when the survival curves cross.
The authors may consider analysing the survival curves
at a fixed point in time [27]. Another alternative includes
using a weighted log-rank (Harrington-Fleming) test
which gives more weight to the later events [28]. Other
weighted log-rank tests that may be useful are the
methods developed by Gill et al. or Pepe and Fleming
[29, 30]. Li et al. recently published a simulation study
which investigated several statistical methods in the
situation of crossing survival curves. This study showed
that adaptive Neyman’s smooth tests and the two-stage
procedure provided greater stability and higher power as
compared to the other methods [29].
Relapse disease and death are the most common out-
comes in the ALL literature. Conventional KM method
and Cox proportional hazard model convey no informa-
tion regarding possible competing risks. Competing risk
is an event that modifies the chance of the interested
outcome [31]. For example, death from any cause is a
competing risk for relapse disease. Using the compet-
ing risk analysis is therefore considered to be more
appropriate in the treatment with high rate of compli-
cations. We observed only one study that used com-
peting risk analysis [11]. We encouraged investigators
to incorporate competing risk analysis, at least in the
sensitivity analysis.
We found that the Cox PH model was commonly used
in the collection of articles in our review. There was
substantial inadequacy of the description of variable
selection, the strategy used for fitting procedure and test
for goodness-of-fit. As mentioned above, sample size
estimation related to regression analysis was noted in
only four studies. Of these, two studies were found to be
underpowered based on low event-per-covariate ratio
[8]. We strongly encourage authors to describe the
process of variable selection, strategy of model building
and provide evidence that the sample size is sufficient
for regression analysis.
A lack of PH assumption checking may introduce bias
to the regression analysis. Our review shows that none
of the studies described an assessment of the PH as-
sumption. The Cox PH model assumes that the hazard
ratio for comparing any two groups of predictor vari-
ables is constant over time [4]. If this assumption is not
met, the Cox PH model is not valid for the analysis. We
observed that 11 of 14 (79 %) studies had crossing
survival curves. A clear violation of the PH assumption
occurs if survival curves cross [32, 33]. Therefore, a
hazard ratio should not be used to compare the treat-
ment effect between groups. We suggest that authors
check for the PH assumption if the Cox PH model is
incorporated in the analysis. When the PH assumption
is violated, authors may consider using an alternative
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or parametric survival analysis (Weibull, exponential,
log-logistic or lognormal model).
Conclusions
Our systematic review evaluating reporting methods for
survival analysis in adult ALL patients undergoing allo-
SCT show significant shortcomings in the use and report-
ing of survival analysis. Sample size estimation was not
routinely described and studies are frequently statistically
underpowered. There was a lack of censoring description.
Most notably, crossing survival curves were common and
none of the studies checked for the PH assumption.
Finally, the description of variable selection, fitting
procedure and model checking were neglected.
Survival analysis has been used increasingly in medical
research studies [6]. We raise awareness of these limita-
tions and encourage authors, reviewers and editors to
improve the quality of the use and reporting survival
analysis in the literature.
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